tesamorelin
tesamorelin is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand names including EGRIFTA WR, EGRIFTA SV. Available dosage form: kit.
Drug details
- Generic Name
- tesamorelin
- Brand Names
- EGRIFTA WR, EGRIFTA SV
- Application Number
- BLA022505
- Sponsor
- Theratechnologies Inc.
- NDC Codes
- 4
- Dosage Forms
- KIT
- Routes
- SUBCUTANEOUS
Indications and Usage
1 INDICATIONS AND USAGE EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. EGRIFTA SV is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. ( 1 ) Limitations of use: Long-term cardiovascular safety of EGRIFTA SV has not been established. ( 1 ) Not indicated for weight loss management. ( 1 ) There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. ( 1 )